On March 3, 2026, Sinopia Biosciences, a biotechnology company advancing novel therapeutics discovered using its proprietary LEADS^®(LEarn And DiScover) drug discovery platform, announced a target discovery collaboration with Ono Pharmaceutical focused on an undisclosed group of rare metabolic disorders with significant unmet medical need. Under the agreement, Sinopia will apply its proprietary metabolomics-driven discovery platform to identify and validate novel therapeutic targets aimed at addressing the underlying biochemical dysfunction that drives disease progression. Ono Pharmaceutical may advance targets, identified through the collaboration, toward the development of new medicines for affected patients. Wilson Sonsini Goodrich & Rosati advised Sinopia Biosciences on the transaction.

Under the terms of the collaboration, Sinopia will receive research funding, an upfront payment, and is eligible for future milestones.

The Wilson Sonsini team that advised Sinopia Biosciences on the transaction was led by Seth Flaum.

For more information, please see Sinopia Biosciences’ news release.